AMP adds Adamas Pharmaceuticals to Hypo Fund


Today, AMP started an initial position in Adamas Pharmaceuticals (ADMS) with a starting position of $12,500. ADMS has a target PDUFA date for it's ADS-5102 program in Parkinson's patients with levodopa induced dyskinesia (LID) of August 24 and AMP is cautiously optimistic of drug's chances of approval.

You can read more about ADMS in our recently published post here.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon